Literature DB >> 6407799

The protective effect of gamma-glutamyl L-dopa on the glycerol treated rat model of acute renal failure.

I F Casson, D A Clayden, G F Cope, M R Lee.   

Abstract

gamma-Glutamyl L-dopa, a renal pro-drug for dopamine, was administered to rats before and after injection of glycerol, and to a control group which received water in place of glycerol. A third group of rats was given glycerol but no gamma-glutamyl L-dopa. The plasma creatinine in rats given gamma-glutamyl L-dopa and glycerol was significantly lower than in rats receiving glycerol alone. The fall in urine creatinine excretion, and polyuria, after glycerol was reduced by gamma-glutamyl L-dopa and the natriuresis abolished. gamma-Glutamyl L-dopa given alone caused a 4000-fold increase in urine dopamine excretion, associated with a natriuresis. The administration of gamma-glutamyl L-dopa reduces the severity of renal failure produced by glycerol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407799     DOI: 10.1042/cs0650159

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  4 in total

Review 1.  Acute renal failure in the intensive care unit. Part 2.

Authors:  H L Corwin; J V Bonventre
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure.

Authors:  Y A Boateng; H E Barber; T M MacDonald; J C Petrie; M R Lee; P H Whiting
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

3.  Regional haemodynamic effects of dopamine and its prodrugs L-dopa and gludopa in the rat and in the glycerol-treated rat as a model for acute renal failure.

Authors:  J C Drieman; F J van Kan; H H Thijssen; H van Essen; J F Smits; H A Struijker Boudier
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

4.  Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers.

Authors:  Y A Boateng; H E Barber; T M MacDonald; J C Petrie; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.